Related Experiment Videos

[Secondary myocardial hypertrophy in a very small premature infant treated with dexamethasone]

E Korsch1, A Gillor, P Groneck

  • 1Kinderkrankenhaus der Stadt Köln.

Insights

Dexamethasone treatment in preterm infants may cause temporary myocardial hypertrophy, indicated by increased heart wall thickness. Echocardiographic monitoring is recommended during and after therapy for bronchopulmonary dysplasia.

Area of Science:

  • Neonatal Medicine
  • Pediatric Cardiology
  • Pharmacology

Background:

  • Bronchopulmonary dysplasia (BPD) is a common complication in preterm infants.
  • Dexamethasone is increasingly used to manage BPD risk.
  • Potential cardiac side effects of dexamethasone in neonates remain under-examined.

Observation:

  • A retrospective analysis of seven preterm infants (mean birth weight 791g, gestational age 26 weeks) receiving dexamethasone was conducted.
  • Echocardiographic assessments were performed during dexamethasone therapy.
  • One patient's case illustrates the observed cardiac changes.

Findings:

  • Dexamethasone therapy was associated with a significant increase in interventricular septum thickness.
  • Left ventricular posterior wall thickness also significantly increased during treatment.
  • These echocardiographic abnormalities resolved after dexamethasone cessation.

Implications:

  • Preterm infants treated with dexamethasone require careful cardiac monitoring.
  • Serial echocardiographic investigations are crucial to detect and manage potential myocardial hypertrophy.
  • This highlights the importance of balancing BPD treatment benefits with cardiac risks.
Abstract

Related Concept Videos